Department of Health and Human Services February 8, 2006 – Federal Register Recent Federal Regulation Documents

This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the inventions embodied in the (1) U.S. Provisional Patent Application 60/195,507, filed April 6, 2000, entitled ``Aminoflavone Compounds, Compositions, and Methods of Use Thereof'' and all related foreign patents/patent applications (HHS Ref. No. E-279-1999/0); (2) U.S. Patent Application 08/014,696, filed February 8, 1993, entitled ``5-Aminoflavone Derivatives'' and all related foreign patents/patent applications (HHS Ref. No. E-296-2005/1); (3) PCT Patent Application PCT/US96/00181, filed August 10, 1994, entitled ``5-Aminoflavone Derivatives, Their Preparation and Their Use as Antibacterial, Anti-estrogenic and/or Antitumor Agent'' and all related foreign patents/patent applications (HHS Ref. No. E-295-2005/ 0), with the exception of the JP patent application JP204356/93, filed on August 18, 1993;

The Food and Drug Administration (FDA) has determined the regulatory review period for ALIMTA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.